Bristol-Myers Squibb Company
NYSE:BMYDrug Manufacturers - General
-$1.42 today
- Market cap
- $121.75B
- Beta
- 0.24
- P/E (TTM)
- 15.1
- EPS (TTM)
- $3.56
- Dividend yield
- 4.64%
Volume 9.54M
Average 11.50M
BMY EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Bristol-Myers Squibb CompanyNYSE: BMY
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of $5.09B rose 55.6% year over year, ahead of the +11.6% change in trailing-twelve-month EBITDA. Sequentially, it rose 19.8% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.
Context
- EBITDA amounted to 31.6% of revenue in FY2025, up 25.0 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 19 analysts of $20.18B (+32.5%) for the fiscal year ending Dec 2026, a slowdown from the +380.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $5.09B+19.8% QoQ
- Last fiscal yearDec 2025
- $15.23B+380.7% YoY
- LTMJun 2026
- $16.82B+11.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +55.6% | -22.9% | -78.5 pp |
| 1 year | +380.7% | +32.5% | -348.2 pp |
| 3-year CAGR | -7.5% | +3.1% | +10.5 pp |
| 5-year CAGR | -0.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 15.23B USD
- Year-over-year change
- +380.7%
- 4-year CAGR
- -6.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.23B | +380.7% |
| FY2024 | 2024-12-31 | 3.17B | -83.6% |
| FY2023 | 2023-12-31 | 19.37B | +0.8% |
| FY2022 | 2022-12-31 | 19.22B | -4.5% |
| FY2021 | 2021-12-31 | 20.12B | — |
EBITDA vs competitors
How BMY compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +11.6% is the 4th highest of 11, against a peer median of +0.1%.
- EBITDA amounts to 34.2% of revenue for BMY, versus a peer median of 32.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $43.3B USD | +103.7% | +54.1% | 54.4% | |
| LTM Sep 2026 | $30.81B USD | -22.1% | +15.6% | 31.0% | |
| LTM Sep 2026 | $24.15B USD | +88.7% | -10.0% | 36.6% | |
| LTM Jun 2026 | $22.26B USD | -2.0% | +16.1% | 40.0% | |
| LTM Sep 2026 | $21.37B USD | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $17.62B USD | +10.8% | +11.6% | 46.2% | |
| LTM Jun 2026 | $16.82B USD | +11.6% | -7.5% | 34.2% | |
| LTM Jun 2026 | $13.93B USD | -44.4% | +9.9% | 21.0% | |
| LTM Jun 2026 | $13.49B USD | -33.1% | -25.8% | 21.2% | |
| LTM Jun 2026 | £8.8B GBP | +2.2% | +6.5% | 26.5% | |
| LTM Jun 2026 | $1.33B USD | -87.8% | +15.3% | 4.4% | |
| Peer median (excluding BMY) | — | +0.1% | +13.4% | 32.7% | |
Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 46.39B | 46.16B | 45.01B | 48.3B | 48.2B |
| Cost of Revenue | 9.94B | 10.14B | 10.69B | 13.97B | 13.94B |
| Gross Profit | 36.45B | 36.02B | 34.31B | 34.33B | 34.26B |
| Gross Margin | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% |
| Research & Development | 10.2B | 9.51B | 9.3B | 11.16B | 9.95B |
| Selling, General & Admin | 7.69B | 7.81B | 7.77B | 8.41B | 7.27B |
| Operating Expenses | 27.91B | 26.92B | 26.12B | 28.45B | 20.54B |
| Depreciation & Amortization | 10.69B | 10.28B | 9.76B | 9.6B | 4.01B |
| EBITDA | 20.12B | 19.22B | 19.37B | 3.17B | 15.23B |
| EBITDA Margin | 43.4% | 41.6% | 43.0% | 6.6% | 31.6% |
| Operating Income | 8.54B | 9.1B | 8.2B | 5.89B | 13.72B |
| Operating Margin | 18.4% | 19.7% | 18.2% | 12.2% | 28.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.33B | 1.23B | 1.17B | 1.95B | 1.89B |
| Other Income / Expenses | (439M) | (1.39B) | 245M | (14.27B) | (4.4B) |
| Income Before Tax | 8.1B | 7.71B | 8.44B | (8.38B) | 9.33B |
| Pre-Tax Margin | 17.5% | 16.7% | 18.8% | -17.3% | 19.4% |
| Income Tax Expense | 1.08B | 1.37B | 400M | 554M | 2.27B |
| Net Income | 6.99B | 6.33B | 8.03B | (8.95B) | 7.05B |
| Net Margin | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% |
| EPS (Basic) | 3.15 | 2.97 | 3.88 | (4.41) | 3.46 |
| EPS (Diluted) | 3.12 | 2.95 | 3.86 | (4.41) | 3.45 |
| Weighted Avg Shares | 2.22B | 2.13B | 2.07B | 2.03B | 2.04B |
| Weighted Avg Shares (Diluted) | 2.25B | 2.15B | 2.08B | 2.03B | 2.04B |
Bristol-Myers Squibb Company
NYSE:BMY
Intrinsic Alpha fair value
Locked
Current Price
$59.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.